Evotec partners with Haplogen to develop drugs for infectious diseases

19-Nov-2012 - Germany

Evotec AG and Haplogen GmbH have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases.

Under the agreement, Haplogen and Evotec will co-develop drugs against a  human protein that is essential for pathogenic viruses to infect their host cell. This protein was discovered by Haplogen's powerful proprietary technology to identify host factors for infectious human pathogens. Evotec will further develop Haplogen's lead compounds and apply its drug discovery platform to find additional small molecule inhibitors.

Terms of the partnership were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances